Neurotransmitter

A neurotransmitter is an endogenous chemical messenger synthesized within a neuron, packaged into membrane-bound vesicles (or synthesized on demand in the case of unconventional messengers), released into the synapse upon Ca²⁺-dependent exocytosis triggered by a presynaptic action potential, and recognized by specific postsynaptic or presynaptic receptors to alter membrane conductance or intracellular signaling cascades. To qualify classically as a neurotransmitter, a molecule must satisfy four experimental criteria: (1) its biosynthetic enzymes and the molecule itself must be present within the presynaptic neuron; (2) it must be released in a Ca²⁺-dependent manner upon presynaptic depolarization; (3) exogenous microapplication of the substance onto the postsynaptic cell must mimic the physiological response to presynaptic stimulation (identity of action); and (4) a dedicated mechanism—either enzymatic degradation or high-affinity transporter reuptake—must exist to terminate its action in the synaptic cleft.

Whether intercellular communication across the synaptic cleft is electrical or chemical remained unresolved until 1921, when the German-born pharmacologist Otto Loewi performed a classic experiment on isolated frog (Rana esculenta) hearts. Loewi electrically stimulated the vagus nerve of a cannulated donor heart, slowing its beat rate, and transferred the surrounding Ringer's perfusate to a second, denervated recipient heart, which promptly slowed at a matching rate. Loewi named the soluble inhibitory substance Vagusstoff ("vagus substance") and also demonstrated that sympathetic stimulation released an cardioacceleratory substance (Acceleransstoff, later identified as epinephrine/norepinephrine). Working alongside Loewi, Henry Hallett Dale identified Vagusstoff chemically as acetylcholine (ACh) and demonstrated its physiological release at parasympathetic terminals, autonomic ganglia, and vertebrate skeletal neuromuscular junctions—discoveries for which Loewi and Dale shared the 1936 Nobel Prize in Physiology or Medicine.

Subsequent biochemical and neurophysiological investigations in the mid-to-late twentieth century expanded the repertoire of known neurotransmitters from acetylcholine and catecholamines (characterized by Ulf von Euler and Julius Axelrod) to simple amino acid derivatives—notably L-glutamate and γ-aminobutyric acid (GABA), established by Eugene Roberts, Jeffrey Watkins, and David Curtis—as well as neuropeptides, purines, endocannabinoids, and dissolved gases such as nitric oxide.

More than 100 distinct signaling molecules function as neurotransmitters in the animal kingdom, broadly categorized into small-molecule neurotransmitters (synthesized locally in the cytosol of the axon terminal and packaged into 35–45 nm small clear-core synaptic vesicles) and neuropeptides (synthesized as prepropeptides on the rough endoplasmic reticulum in the soma, processed in the Golgi apparatus, and transported via fast axonal transport in 80–120 nm large dense-core vesicles [LDCVs]).

Amino Acid Neurotransmitters

Amino acids mediate the vast majority of fast point-to-point synaptic transmission in the central nervous system (CNS):

• L-Glutamate: The primary excitatory neurotransmitter at >80% of synapses in the vertebrate CNS (and at arthropod neuromuscular junctions). Because systemic glutamate cannot cross the blood–brain barrier, synaptic glutamate is synthesized locally in presynaptic terminals from glutamine via mitochondrial phosphate-activated glutaminase (PAG) as part of the glutamate–glutamine cycle with surrounding astrocytes.
• γ-Aminobutyric Acid (GABA): The primary fast inhibitory neurotransmitter throughout the vertebrate brain (and at crustacean inhibitory neuromuscular junctions). GABA is synthesized directly from L-glutamate via α-decarboxylation catalyzed by glutamic acid decarboxylase (GAD65 at synaptic terminals and GAD67 in the soma), which requires pyridoxal phosphate (PLP), the active form of vitamin B₆, as an essential cofactor. Consequently, severe vitamin B₆ deficiency or PLP-antagonist poisoning impairs GABA synthesis and triggers status epilepticus seizures.
• Glycine: The simplest amino acid, synthesized from L-serine by mitochondrial serine hydroxymethyltransferase, serving as the major fast inhibitory neurotransmitter in the vertebrate spinal cord, brainstem, and retina (as well as an obligatory co-agonist with glutamate at central NMDA receptors).

Acetylcholine and Monoamines

• Acetylcholine (ACh): Synthesized in the cytoplasm of cholinergic terminals from acetyl-CoA (generated by mitochondrial pyruvate dehydrogenase) and dietary choline (imported via the high-affinity Na⁺-dependent choline transporter CHT1, the rate-limiting step in ACh synthesis) by the enzyme choline acetyltransferase (ChAT). ACh mediates excitation at all vertebrate skeletal neuromuscular junctions, all preganglionic autonomic synapses, postganglionic parasympathetic synapses, and basal forebrain projections (nucleus basalis of Meynert) modulating cortical arousal and attention.
• Catecholamines (Dopamine, Norepinephrine, Epinephrine): Derived sequentially from the aromatic amino acid L-tyrosine:

1. Tyrosine hydroxylase (TH)—the rate-limiting enzyme, requiring tetrahydrobiopterin (BH₄) and O₂—hydroxylates L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine).
2. Aromatic L-amino acid decarboxylase (AADC / DOPA decarboxylase) converts L-DOPA into dopamine (DA), which acts in nigrostriatal (motor control) and mesocorticolimbic (reward prediction error and motivation) pathways.
3. In noradrenergic neurons (such as the locus coeruleus and sympathetic postganglionic fibers), vesicular dopamine β-hydroxylase (DBH)—an ascorbate- and Cu²⁺-dependent enzyme located inside synaptic vesicles—converts dopamine into norepinephrine (noradrenaline, NE).
4. In adrenergic brainstem neurons and chromaffin cells of the adrenal medulla, cytosolic phenylethanolamine N-methyltransferase (PNMT) transfers a methyl group from S-adenosylmethionine (SAM) to norepinephrine to yield epinephrine (adrenaline).

• Serotonin (5-Hydroxytryptamine, 5-HT): An indolamine synthesized in the raphe nuclei of the brainstem from dietary L-tryptophan via two steps: hydroxylation by rate-limiting tryptophan hydroxylase-2 (TPH2) to 5-hydroxytryptophan (5-HTP), followed by decarboxylation by AADC to 5-HT.
• Histamine: Synthesized from L-histidine by histidine decarboxylase in neurons of the hypothalamic tuberomammillary nucleus, promoting wakefulness and cortical arousal.

Neuropeptides, Purines, and Unconventional Messengers

• Neuropeptides: Include endogenous opioids (β-endorphin, met-enkephalin, leu-enkephalin, and dynorphins cleaved from POMC, proenkephalin, and prodynorphin precursors), substance P (nociceptive transmission), oxytocin and vasopressin, neuropeptide Y (NPY), and orexins/hypocretins. Unlike small-molecule transmitters, LDCV exocytosis requires sustained, high-frequency action-potential bursts that elevate bulk cytosolic [Ca²⁺]_in away from active-zone microdomains.
• Purines: ATP is co-packaged into synaptic vesicles alongside classical transmitters and acts on ionotropic P2X receptors and metabotropic P2Y receptors; extracellular ectonucleotidases rapidly hydrolyze ATP to adenosine, which activates inhibitory A₁ and excitatory A_2A receptors (the primary molecular targets antagonized by caffeine).
• Unconventional Retrograde Messengers: Endocannabinoids—principally 2-arachidonoylglycerol (2-AG) and anandamide (AEA)—are lipid derivatives cleaved on demand from postsynaptic membrane phospholipids during Ca²⁺ elevation; they diffuse retrogradely across the synaptic cleft to activate presynaptic G_i/o-coupled CB₁ receptors, suppressing further vesicular release. Similarly, nitric oxide (NO) is a membrane-permeant free-radical gas synthesized from L-arginine by Ca²⁺/calmodulin-activated neuronal nitric oxide synthase (nNOS), diffusing freely into neighboring cells to stimulate soluble guanylyl cyclase (sGC) and generate cyclic GMP (cGMP).

A key principle of neurobiology is that the physiological effect of a neurotransmitter—whether excitatory or inhibitory, millisecond-fast or seconds-long—is determined entirely by the postsynaptic receptor to which it binds, rather than by the chemical structure of the transmitter itself.

Ionotropic Receptors (Ligand-Gated Ion Channels)

Ionotropic receptors are multimeric transmembrane proteins that contain both an extracellular neurotransmitter-binding site (orthosteric site) and an intrinsic, membrane-spanning ion pore. Ligand binding induces an allosteric conformational transition within microseconds, gating ion flux for 1–50 ms. Three evolutionary superfamilies exist in vertebrates:

1. Cys-Loop Pentameric Receptors: Composed of five subunits arranged around a central pore, each containing a characteristic 13-amino-acid disulfide loop in the extracellular domain. This family includes cation-selective excitatory channels—nicotinic acetylcholine receptors (nAChRs) (α₂βγδ at muscle endplates; α₄β₂ or homomeric α₇ in brain) and 5-HT₃ serotonin receptors—as well as anion-selective (Cl⁻) inhibitory channels—GABA_A receptors (modulated allosterically by benzodiazepines, barbiturates, neurosteroids, and propofol) and strychnine-sensitive glycine receptors (GlyRs).
2. Ionotropic Glutamate Receptors (iGluRs): Tetrameric complexes (dimers of dimers) featuring a membrane-reentrant pore loop (M2) structurally homologous to inverted K⁺ channels. Divided into AMPA receptors (GluA1–4; mediate fast EPSPs; GluA2-containing heterotetramers are edited at the Q/R site to block Ca²⁺ permeability), kainate receptors (GluK1–5), and NMDA receptors (obligate heterotetramers of two glycine/D-serine-binding GluN1 subunits and two glutamate-binding GluN2A–D subunits, characterized by voltage-dependent Mg²⁺ block and high Ca²⁺ permeability).
3. Trimeric P2X Purinergic Receptors: Composed of three subunits with two transmembrane domains each, opening a non-selective cation pore (Na⁺, K⁺, Ca²⁺) upon extracellular ATP binding.

Metabotropic Receptors (G-Protein-Coupled Receptors)

Metabotropic receptors are monomeric or dimeric seven-transmembrane-helix G-protein-coupled receptors (GPCRs) lacking an intrinsic ion pore. Neurotransmitter binding catalyzes the exchange of GDP for GTP on the α-subunit of an intracellular heterotrimeric G-protein (Gαβγ), initiating slower (100 ms to minutes) biochemical cascades that amplify signals and modulate ion channels or gene transcription:

• G_s-coupled receptors (e.g., β₁/β₂-adrenergic, D₁/D₅ dopamine, 5-HT_4/6/7, H₂ histamine) stimulate adenylyl cyclase, raising intracellular cAMP and activating protein kinase A (PKA), which phosphorylates L-type Ca²⁺ channels, AMPA receptors, and the transcription factor CREB.
• G_i/o-coupled receptors (e.g., α₂-adrenergic, D₂–D₄ dopamine, M₂/M₄ muscarinic, GABA_B, μ/δ/κ-opioid, CB₁ cannabinoid, Group II/III mGluRs) inhibit adenylyl cyclase while their liberated Gβγ dimers diffuse within the membrane plane to directly open G-protein-coupled inwardly rectifying K⁺ (GIRK / K_ir3) channels (hyperpolarizing the postsynaptic membrane, as in vagal ACh slowing of the sinoatrial node via M₂ receptors) and inhibit presynaptic Ca_V2.1/2.2 channels.
• G_q/11-coupled receptors (e.g., α₁-adrenergic, M₁/M₃/M₅ muscarinic, 5-HT_2A–C, Group I mGluR1/5, H₁ histamine) activate phospholipase C-β (PLCβ), hydrolyzing membrane phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) (which releases Ca²⁺ from endoplasmic reticulum stores) and diacylglycerol (DAG) (which activates protein kinase C [PKC]).

Proton-Driven Vesicular Packaging

Concentrating small-molecule neurotransmitters inside synaptic vesicles to intraluminal concentrations of 100–500 mM (~1,000-fold higher than the cytosol) requires secondary active transport driven by a vacuolar-type H⁺-ATPase (V-ATPase). The V-ATPase pumps protons into the vesicle lumen, establishing an acidic luminal pH (~5.5; ΔpH ≈ 1.7 units) and an inside-positive electrical potential (Δ*Ψ* ≈ +40 to +60 mV). Four distinct vesicular antiporters exploit different components of this proton motive force:

• VGLUT1–3 (Vesicular Glutamate Transporters): Driven primarily by the positive electrical gradient Δ*Ψ* to import negatively charged glutamate anions.
• VGAT / VIAAT (Vesicular Inhibitory Amino Acid Transporter): Packages both zwitterionic GABA and glycine via H⁺ exchange driven equally by ΔpH and Δ*Ψ*.
• VMAT2 (Vesicular Monoamine Transporter 2, and adrenal VMAT1) and VAChT (Vesicular Acetylcholine Transporter): Exchange 2 luminal H⁺ ions for 1 cytosolic cationic monoamine or ACh⁺, relying predominantly on the chemical gradient ΔpH (and inhibited pharmacologically by the antihypertensive alkaloid reserpine in the case of VMAT).

Reuptake Transporters vs. Enzymatic Degradation

Rapid clearance of neurotransmitters from the synaptic cleft prevents receptor desensitization and maintains temporal precision:

1. Enzymatic Hydrolysis (Acetylcholine): Uniquely among classical transmitters, ACh is terminated directly inside the synaptic cleft by acetylcholinesterase (AChE), a catalytic triad (Ser-His-Glu) enzyme anchored to the basal lamina. Operating near the physical diffusion limit (k_cat ≈ 1.4 × 10⁴ s⁻¹; k_cat/K_M ≈ 1.6 × 10⁸ M⁻¹ s⁻¹), AChE hydrolyzes ACh into acetate and choline in <1 ms. Reversible AChE inhibitors (neostigmine, pyridostigmine, donepezil) treat myasthenia gravis and Alzheimer's disease, whereas irreversible organophosphate nerve agents (sarin, VX) and carbamate insecticides phosphorylate the active-site serine, causing fatal cholinergic crisis.
2. Na⁺-Coupled Plasma-Membrane Reuptake: Amino acids and monoamines are cleared by secondary active symporters powered by the transmembrane Na⁺ gradient. Excitatory amino acid transporters (EAAT1–5)—especially astrocytic EAAT2 (GLT-1)—cotransport 1 glutamate⁻ with 3 Na⁺ and 1 H⁺ in while countertransporting 1 K⁺ out, keeping basal extracellular glutamate below 25 nM to prevent NMDA-mediated excitotoxicity. In the SLC6 family of Na⁺/Cl⁻-dependent transporters, GAT1 clears GABA, while DAT, NET, and SERT clear dopamine, norepinephrine, and serotonin (serving as the primary pharmacological targets of cocaine, amphetamines, tricyclic antidepressants, and selective serotonin reuptake inhibitors [SSRIs]). Intracellularly, monoamines are catabolized by outer-mitochondrial monoamine oxidase (MAO-A and MAO-B) and catechol-O-methyltransferase (COMT).

Can the same neurotransmitter be both excitatory and inhibitory?

Yes. A neurotransmitter's physiological action is determined by the postsynaptic receptor and the ionic gradients of the target cell, not by the molecule itself. For example, acetylcholine is strongly excitatory at skeletal muscle fibers, where it opens nicotinic cation channels (nAChRs) to allow Na⁺ influx, but is strongly inhibitory at sinoatrial pacemaker cells of the heart, where it binds metabotropic M₂ muscarinic receptors whose Gβγ subunits open GIRK K⁺ channels to hyperpolarize the cell.

Why is GABA excitatory during early embryonic brain development?

In mature central neurons, the K⁺/Cl⁻ cotransporter KCC2 extrudes Cl⁻, keeping intracellular [Cl⁻]_in low (~5 mM) so that E_Cl (~−75 mV) is negative to the resting potential and GABA_A channel opening causes hyperpolarizing Cl⁻ influx. In immature embryonic and neonatal neurons, KCC2 expression is low while the Na⁺-K⁺-2Cl⁻ importer NKCC1 is high, elevating [Cl⁻]_in to ~25–30 mM (E_Cl ≈ −40 mV) so that GABA_A activation triggers depolarizing Cl⁻ efflux that guides synaptogenesis.

What is glutamate excitotoxicity and why does it occur during a stroke?

Glutamate is present inside synaptic vesicles at ~100 mM and in neuronal cytosol at ~10 mM, whereas extracellular cleft concentrations must be maintained below 1 μM by Na⁺-dependent astrocytic EAAT2 transporters. During ischemic stroke, oxygen and glucose deprivation halts mitochondrial ATP synthesis, causing failure of the Na⁺/K⁺-ATPase pump. Collapse of the transmembrane Na⁺ gradient reverses EAAT transporters, dumping glutamate into the extracellular space and overactivating NMDA receptors to trigger lethal Ca²⁺-induced neuronal necrosis and apoptosis.

1. Südhof, T. C. (2012). "The presynaptic active zone." Neuron, 75(1), 11–25. https://doi.org/10.1016/j.neuron.2012.06.012
2. Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010). "Glutamate receptor ion channels: structure, regulation, and function." Pharmacological Reviews, 62(3), 405–496. https://doi.org/10.1124/pr.109.002451
3. Blakely, R. D., & Edwards, R. H. (2012). "Vesicular and plasma membrane transporters for neurotransmitters." Cold Spring Harbor Perspectives in Biology, 4(2), a005595. https://doi.org/10.1101/cshperspect.a005595
4. Smart, T. G., & Paoletti, P. (2012). "Synaptic neurotransmitter-gated receptors." Cold Spring Harbor Perspectives in Biology, 4(3), a009662. https://doi.org/10.1101/cshperspect.a009662